Annual FCF
-$19.81 M
+$5.06 M+20.34%
31 December 2023
Summary:
Aileron Therapeutics annual free cash flow is currently -$19.81 million, with the most recent change of +$5.06 million (+20.34%) on 31 December 2023. During the last 3 years, it has risen by +$673.00 thousand (+3.29%). ALRN annual FCF is now -67.81% below its all-time high of -$11.80 million, reached on 31 December 2015.ALRN Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$3.82 M
+$4.57 M+54.48%
30 September 2024
Summary:
Aileron Therapeutics quarterly free cash flow is currently -$3.82 million, with the most recent change of +$4.57 million (+54.48%) on 30 September 2024. Over the past year, it has dropped by -$2.18 million (-132.87%). ALRN quarterly FCF is now -132.87% below its all-time high of -$1.64 million, reached on 30 September 2023.ALRN Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$27.87 M
-$2.18 M-8.48%
30 September 2024
Summary:
Aileron Therapeutics TTM free cash flow is currently -$27.87 million, with the most recent change of -$2.18 million (-8.48%) on 30 September 2024. Over the past year, it has dropped by -$14.04 million (-101.58%). ALRN TTM FCF is now -643.60% below its all-time high of -$3.75 million, reached on 31 March 2016.ALRN TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALRN Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +20.3% | -132.9% | -101.6% |
| 3 y3 years | +3.3% | +47.4% | -24.7% |
| 5 y5 years | +38.8% | +45.3% | +3.6% |
ALRN Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +20.3% | -132.9% | +63.3% | -101.6% | at low |
| 5 y | 5 years | at high | +38.8% | -132.9% | +63.3% | -101.6% | +3.6% |
| alltime | all time | -67.8% | +38.8% | -132.9% | +63.3% | -643.6% | +15.7% |
Aileron Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.82 M(-54.5%) | -$27.87 M(+8.5%) |
| June 2024 | - | -$8.39 M(+59.2%) | -$25.69 M(+25.8%) |
| Mar 2024 | - | -$5.27 M(-49.3%) | -$20.42 M(+3.1%) |
| Dec 2023 | -$19.81 M(-20.3%) | -$10.39 M(+533.6%) | -$19.81 M(+43.3%) |
| Sept 2023 | - | -$1.64 M(-47.4%) | -$13.83 M(-27.8%) |
| June 2023 | - | -$3.12 M(-33.1%) | -$19.16 M(-11.8%) |
| Mar 2023 | - | -$4.66 M(+5.7%) | -$21.73 M(-12.6%) |
| Dec 2022 | -$24.86 M(+4.0%) | -$4.41 M(-36.8%) | -$24.86 M(-6.9%) |
| Sept 2022 | - | -$6.97 M(+22.6%) | -$26.71 M(-1.1%) |
| June 2022 | - | -$5.68 M(-27.1%) | -$27.00 M(+7.4%) |
| Mar 2022 | - | -$7.80 M(+24.7%) | -$25.15 M(+5.2%) |
| Dec 2021 | -$23.91 M(+16.7%) | -$6.25 M(-13.9%) | -$23.91 M(+7.0%) |
| Sept 2021 | - | -$7.26 M(+89.7%) | -$22.34 M(+11.0%) |
| June 2021 | - | -$3.83 M(-41.6%) | -$20.12 M(-5.8%) |
| Mar 2021 | - | -$6.56 M(+39.9%) | -$21.37 M(+4.3%) |
| Dec 2020 | -$20.48 M | -$4.69 M(-7.0%) | -$20.48 M(-7.4%) |
| Sept 2020 | - | -$5.04 M(-0.7%) | -$22.11 M(-8.1%) |
| June 2020 | - | -$5.08 M(-10.5%) | -$24.05 M(-2.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$5.67 M(-10.3%) | -$24.67 M(-7.3%) |
| Dec 2019 | -$26.63 M(-17.7%) | -$6.32 M(-9.5%) | -$26.63 M(-7.9%) |
| Sept 2019 | - | -$6.98 M(+22.6%) | -$28.90 M(-7.0%) |
| June 2019 | - | -$5.70 M(-25.3%) | -$31.07 M(-6.0%) |
| Mar 2019 | - | -$7.63 M(-11.3%) | -$33.04 M(+2.1%) |
| Dec 2018 | -$32.35 M(+56.5%) | -$8.60 M(-6.1%) | -$32.35 M(+9.1%) |
| Sept 2018 | - | -$9.16 M(+19.5%) | -$29.66 M(+15.1%) |
| June 2018 | - | -$7.66 M(+10.5%) | -$25.77 M(+19.2%) |
| Mar 2018 | - | -$6.94 M(+17.4%) | -$21.62 M(+4.6%) |
| Dec 2017 | -$20.67 M(+37.7%) | -$5.91 M(+12.2%) | -$20.67 M(+8.8%) |
| Sept 2017 | - | -$5.26 M(+49.8%) | -$19.00 M(+7.6%) |
| June 2017 | - | -$3.51 M(-41.3%) | -$17.66 M(+2.4%) |
| Mar 2017 | - | -$5.99 M(+41.5%) | -$17.26 M(+14.9%) |
| Dec 2016 | -$15.01 M(+27.2%) | -$4.23 M(+7.8%) | -$15.01 M(+39.3%) |
| Sept 2016 | - | -$3.93 M(+26.4%) | -$10.78 M(+57.3%) |
| June 2016 | - | -$3.11 M(-17.1%) | -$6.86 M(+82.9%) |
| Mar 2016 | - | -$3.75 M | -$3.75 M |
| Dec 2015 | -$11.80 M | - | - |
FAQ
- What is Aileron Therapeutics annual free cash flow?
- What is the all time high annual FCF for Aileron Therapeutics?
- What is Aileron Therapeutics annual FCF year-on-year change?
- What is Aileron Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Aileron Therapeutics?
- What is Aileron Therapeutics quarterly FCF year-on-year change?
- What is Aileron Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Aileron Therapeutics?
- What is Aileron Therapeutics TTM FCF year-on-year change?
What is Aileron Therapeutics annual free cash flow?
The current annual FCF of ALRN is -$19.81 M
What is the all time high annual FCF for Aileron Therapeutics?
Aileron Therapeutics all-time high annual free cash flow is -$11.80 M
What is Aileron Therapeutics annual FCF year-on-year change?
Over the past year, ALRN annual free cash flow has changed by +$5.06 M (+20.34%)
What is Aileron Therapeutics quarterly free cash flow?
The current quarterly FCF of ALRN is -$3.82 M
What is the all time high quarterly FCF for Aileron Therapeutics?
Aileron Therapeutics all-time high quarterly free cash flow is -$1.64 M
What is Aileron Therapeutics quarterly FCF year-on-year change?
Over the past year, ALRN quarterly free cash flow has changed by -$2.18 M (-132.87%)
What is Aileron Therapeutics TTM free cash flow?
The current TTM FCF of ALRN is -$27.87 M
What is the all time high TTM FCF for Aileron Therapeutics?
Aileron Therapeutics all-time high TTM free cash flow is -$3.75 M
What is Aileron Therapeutics TTM FCF year-on-year change?
Over the past year, ALRN TTM free cash flow has changed by -$14.04 M (-101.58%)